Novonix (NVX) Current Deferred Revenue (2020 - 2025)

Novonix's Current Deferred Revenue history spans 6 years, with the latest figure at $146475.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 16.2% year-over-year to $146475.0; the TTM value through Dec 2025 reached $146475.0, up 16.2%, while the annual FY2025 figure was $146475.0, 16.2% up from the prior year.
  • Current Deferred Revenue reached $146475.0 in Q4 2025 per NVX's latest filing, up from $126056.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $285221.0 in Q4 2023 to a low of $2820.7 in Q2 2022.
  • Average Current Deferred Revenue over 5 years is $145225.6, with a median of $136265.5 recorded in 2024.
  • Peak YoY movement for Current Deferred Revenue: plummeted 98.82% in 2022, then skyrocketed 296.22% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $238795.6 in 2021, then crashed by 69.85% to $71985.0 in 2022, then surged by 296.22% to $285221.0 in 2023, then tumbled by 55.8% to $126056.0 in 2024, then increased by 16.2% to $146475.0 in 2025.
  • Per Business Quant, the three most recent readings for NVX's Current Deferred Revenue are $146475.0 (Q4 2025), $126056.0 (Q4 2024), and $285221.0 (Q4 2023).